{"DataElement":{"publicId":"2518237","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 045 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_045_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2518236","version":"1","preferredName":"045 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 045 protocol.","longName":"045_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Does the patient have histologically proven stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma? (This may include tumors of non-keratinizing histology such as basoloid, transitional cell, or cloacogenic histology.)","valueDescription":"Does the patient have histologically proven stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma? (This may include tumors of non-keratinizing histology such as basoloid, transitional cell, or cloacogenic histology.)","ValueMeaning":{"publicId":"2580736","version":"1","preferredName":"Does the patient have histologically proven stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma? (This may include tumors of non-keratinizing histology such as basoloid, transitional cell, or cloacogenic histology.)","longName":"2580736","preferredDefinition":"Does the patient have histologically proven stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma? (This may include tumors of non-keratinizing histology such as basoloid, transitional cell, or cloacogenic histology.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-086D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC9C02F-ADD0-2222-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Does the patient have documented HIV infection? (Documentation may be by antibody detection, culture, or quantitative assay of plasma HIV RNA.)","valueDescription":"Does the patient have documented HIV infection? (Documentation may be by antibody detection, culture, or quantitative assay of plasma HIV RNA.)","ValueMeaning":{"publicId":"2580737","version":"1","preferredName":"Does the patient have documented HIV infection? (Documentation may be by antibody detection, culture, or quantitative assay of plasma HIV RNA.)","longName":"2580737","preferredDefinition":"Does the patient have documented HIV infection? (Documentation may be by antibody detection, culture, or quantitative assay of plasma HIV RNA.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-086E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC9C02F-ADE2-2222-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Has the patient had no prior chemotherapy or no prior irradiation for this malignancy? (Patients with a history of prior irradiation to the planned irradiation field for another condition (eg, Kaposi's sarcoma) may be eligible after consultation.)","valueDescription":"Has the patient had no prior chemotherapy or no prior irradiation for this malignancy? (Patients with a history of prior irradiation to the planned irradiation field for another condition (eg, Kaposi's sarcoma) may be eligible after consultation.)","ValueMeaning":{"publicId":"2580738","version":"1","preferredName":"Has the patient had no prior chemotherapy or no prior irradiation for this malignancy? (Patients with a history of prior irradiation to the planned irradiation field for another condition (eg, Kaposi's sarcoma) may be eligible after consultation.)","longName":"2580738","preferredDefinition":"Has the patient had no prior chemotherapy or no prior irradiation for this malignancy? (Patients with a history of prior irradiation to the planned irradiation field for another condition (eg, Kaposi's sarcoma) may be eligible after consultation.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-086F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC9C02F-ADF4-2222-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Karnofsky Performance Status (must be > 60%)","valueDescription":"Karnofsky Performance Status (must be > 60%)","ValueMeaning":{"publicId":"2580739","version":"1","preferredName":"Karnofsky Performance Status (must be > 60%)","longName":"2580739","preferredDefinition":"Karnofsky Performance Status (must be > 60%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC9C02F-AE06-2222-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Patient's age (in years)","valueDescription":"Patient's age (in years)","ValueMeaning":{"publicId":"2580740","version":"1","preferredName":"Patient's age (in years)","longName":"2580740","preferredDefinition":"Patient's age (in years)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0871-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC9C02F-AE18-2222-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Does the patient have adequate hematologic function within 14 days of study enrollment: Hemoglobin >= 10 g/dl, Platelet count >= 100,000/mm^3, and ANC >= 1500/mm^3?","valueDescription":"Does the patient have adequate hematologic function within 14 days of study enrollment: Hemoglobin >= 10 g/dl, Platelet count >= 100,000/mm^3, and ANC >= 1500/mm^3?","ValueMeaning":{"publicId":"2580741","version":"1","preferredName":"Does the patient have adequate hematologic function within 14 days of study enrollment: Hemoglobin >= 10 g/dl, Platelet count >= 100,000/mm^3, and ANC >= 1500/mm^3?","longName":"2580741","preferredDefinition":"Does the patient have adequate hematologic function within 14 days of study enrollment: Hemoglobin >= 10 g/dl, Platelet count >= 100,000/mm^3, and ANC >= 1500/mm^3?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0872-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCA57C0-98A2-1113-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Does the patient have creatinine <= 1.5 X the upper limits of normal (ULN) or a creatinine clearance above 60 mL/min within 14 days of study enrollment?","valueDescription":"Does the patient have creatinine <= 1.5 X the upper limits of normal (ULN) or a creatinine clearance above 60 mL/min within 14 days of study enrollment?","ValueMeaning":{"publicId":"2580742","version":"1","preferredName":"Does the patient have creatinine <= 1.5 X the upper limits of normal (ULN) or a creatinine clearance above 60 mL/min within 14 days of study enrollment?","longName":"2580742","preferredDefinition":"Does the patient have creatinine <= 1.5 X the upper limits of normal (ULN) or a creatinine clearance above 60 mL/min within 14 days of study enrollment?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0873-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCA57C0-98B4-1113-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Does the patient have adequate hepatic function within 14 days of study enrollment: AST and ALT <= 3 X ULN, and T. Bili <= 2 X ULN? (If related to antiretroviral use, then the Direct Bilirubin must be <= 2 X ULN.)","valueDescription":"Does the patient have adequate hepatic function within 14 days of study enrollment: AST and ALT <= 3 X ULN, and T. Bili <= 2 X ULN? (If related to antiretroviral use, then the Direct Bilirubin must be <= 2 X ULN.)","ValueMeaning":{"publicId":"2580743","version":"1","preferredName":"Does the patient have adequate hepatic function within 14 days of study enrollment: AST and ALT <= 3 X ULN, and T. Bili <= 2 X ULN? (If related to antiretroviral use, then the Direct Bilirubin must be <= 2 X ULN.)","longName":"2580743","preferredDefinition":"Does the patient have adequate hepatic function within 14 days of study enrollment: AST and ALT <= 3 X ULN, and T. Bili <= 2 X ULN? (If related to antiretroviral use, then the Direct Bilirubin must be <= 2 X ULN.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0874-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCA57C0-98C6-1113-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Does the patient have the ability and willingness to give informed consent?","valueDescription":"Does the patient have the ability and willingness to give informed consent?","ValueMeaning":{"publicId":"2580744","version":"1","preferredName":"Does the patient have the ability and willingness to give informed consent?","longName":"2580744","preferredDefinition":"Does the patient have the ability and willingness to give informed consent?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0875-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCA57C0-98D8-1113-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Date informed consent obtained","valueDescription":"Date informed consent obtained","ValueMeaning":{"publicId":"2580745","version":"1","preferredName":"Date informed consent obtained","longName":"2580745","preferredDefinition":"Date informed consent obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCA57C0-98EA-1113-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC989ED-7BE4-11E5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC989ED-7BF9-11E5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}